Climate change has led to the frequent occurrence of high-temperature weather, which has various adverse effects on health, ranging from blood metabolism to systemic organ function. In particular, the sequelae of heat stress injury in most people are related to the nervous system. However, the mechanisms between heat stress and mental health conditions, especially heat stress and anxiety, remain unclear. We attempted to elucidate the effect of heat exposure intervention on anxiety levels in the population and its mechanism. We first carried out a randomized controlled trial in 20 college students in Beijing, China, to observe the results of the effects of heat exposure intervention on human anxiety. Then, we collected blood samples before and after heat exposure experiment and used metabolomic and transcriptomic approaches to quantify serum metabolites and ELISA measurements to explore the underlying mechanisms. We found that even 1.5-hour heat exposure intervention significantly increased anxiety levels. Heat stress-induced anxiety was mediated by the activation of the HPA axis, inflammation, oxidative stress, and subsequently unbalanced neurotransmitters. Metabolites such as BDNF, GABA, and glucocorticoids released by the adrenal glands are biomarkers of heat stress-induced anxiety. We have demonstrated a causal link between heat stress and anxiety, explored possible biological pathway between heat stress and anxiety. Heat stress can cause the activation of the HPA axis and lead to changes in the body's metabolism, resulting in a series of changes such as inflammation and oxidative stress, leading to anxiety. This study reveals hidden health cost of climate change that has been underexplored, and also reminds us the importance of immediate climate actions.
Non-communicable chronic diseases pose a significant public health challenge worldwide. China has launched a nationwide standardized Chronic Disease Patient Management program to provide primary care for patients with hypertension and type 2 diabetes, but its effect on reducing risks of other chronic diseases remains unclear. Here we show, using linked health profiles and medical records from 26 million residents in Shenzhen, China, that program enrollment is associated with lower comorbidity risk among 701,759 patients with newly diagnosed hypertension and 320,179 patients with newly diagnosed type 2 diabetes between 2017 and 2023. Instrumental variable analyses indicate that enrollment reduces overall comorbidity risk by 9% and 14%, respectively. Participants show lower risks for more than 20 chronic diseases. Intervention-specific analyses reveal heterogeneous effects, with alcohol-use, medication-adherence, and psychological support interventions reducing risks of multiple chronic diseases in both patient groups, whereas smoking cessation intervention shows more complex risk patterns among patients with hypertension. These findings support standardized chronic disease management for reducing comorbidity risk and highlight the need for personalized follow-up.